Extensively drug-resistant Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan: microbiologic characteristics, clinical features, and outcomes

Diagnostic Microbiology and Infectious Disease

Volumn 60, Issue 2, 2008, Pages 205-210

  Tan, Che Kim ^a,b   Liaw, Shwu Jen ^a,c   Yu, Chong Jen ^a   Teng, Lee Jene ^a,c   Hsueh, Po Ren ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Clinical features; Colonization; Extensively drug resistant; Infection; Outcomes; Stenotrophomonas maltophilia

Indexed keywords

AZTREONAM; CEFTAZIDIME; COTRIMOXAZOLE; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM ISOLATE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG SCREENING; FEMALE; GENOTYPE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; MALE; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA; TAIWAN; TERTIARY HEALTH CARE;

AGED; AGED, 80 AND OVER; BACTEREMIA; BACTERIAL TYPING TECHNIQUES; CLUSTER ANALYSIS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENOTYPE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; STENOTROPHOMONAS MALTOPHILIA; TAIWAN;

EID: 38149140238     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.09.007     Document Type: Article

References (36)

1. Alfieri N., Ramotar K., Armstrong P., Spornitz M.E., Ross G., Winnick J., and Cook D.R. Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing. Infect. Control Hosp. Epidemiol. 20 (1999) 553-556
2. Carmeli Y., and Samore M.H. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin. Infect. Dis. 24 (1997) 1131-1134
3. Caylan R., Yilmaz G., Sucu N., Bayraktar O., Aydin K., Kaklikkaya N., Aydin F., and Koksal I. Nosocomial Stenotrophomonas maltophilia infections in a university hospital. Mikrobiyol. Bul. 39 (2005) 25-33
4. Cheng N.C., Hsueh P.R., Liu Y.C., Shyr J.M., Huang W.K., Teng L.J., and Liu C.Y. In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. Microb. Drug Resist. 11 (2005) 330-341
5. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standards, M7-A4. 5th ed. (2000), CLSI, Wayne (PA)
6. CLSI. Performance Standards for Antimicrobial Disk Susceptibility Test. Approved Standards, M2-A8. 8th ed. (2003), CLSI, Wayne(PA)
7. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 15th Informational Supplement, M100-S16 (2006), CLSI, Wayne (PA)
8. del Toro M.D., Rodriguez-Bano J., Herrero M., Rivero A., Garcia-Ordonez M.A., Corzo J., and Perez-Cano R. Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine (Baltimore) 81 (2002) 228-239
9. Di Bonaventura G., Spedicato I., D'Antonio D., Robuffo I., and Piccolomini R. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob. Agents Chemother. 48 (2004) 151-160
10. Donlan R.M. Biofilms: microbial life on surfaces. Emerg. Infect. Dis. 8 (2002) 881-890
11. Emori T.G., Culver D.H., Horan T.C., Jarvis W.R., White J.W., Olson D.R., Banerjee S., Edwards J.R., Martone W.J., Gaynes R.P., et al. National Nosocomial Infections Surveillance System (NNIS): description of surveillance methods. Am J. Infect. Control 19 (1991) 19-35
12. Gopalakrishnan R., Hawley H.B., Czachor J.S., Markert R.J., and Bernstein J.M. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals: a study of 143 patients. Heart Lung 28 (1999) 134-141
13. Hsueh P.R., Teng L.J., Yang P.C., Chen Y.C., Ho S.W., and Luh K.T. Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J. Clin. Microbiol. 36 (1998) 1347-1351
14. Hsueh P.R., Liu Y.C., Yang D., Yan J.J., Wu T.L., Huang W.K., Wu J.J., Ko W.C., Leu H.S., Yu C.R., and Luh K.T. Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb. Drug Resist. 7 (2001) 373-382
15. Hsueh P.R., Chen M.L., Sun C.C., Chen W.H., Pan H.J., Yang L.S., Chang S.C., Ho S.W., Lee C.Y., Hsieh W.C., and Luh K.T. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg. Infect. Dis. 8 (2002) 63-68
16. Hsueh P.R., Teng L.J., Chen C.Y., Chen W.H., Yu C.J., Ho S.W., and Luh K.T. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg. Infect. Dis. 8 (2002) 827-832
17. Hsueh P.R., Tseng S.P., Teng L.J., and Ho S.W. Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan. Clin. Microbiol. Infect. 11 (2005) 670-673
18. Hulisz D.T., and File T.M. Predisposing factors and antibiotic use in nosocomial infections caused by Xanthomonas maltophilia. Infect. Control Hosp. Epidemiol. 13 (1992) 489-490
19. Lai C.H., Chi C.Y., Chen H.P., Chen T.L., Lai C.J., Fung C.P., Yu K.W., Wong W.W., and Liu C.Y. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J. Microbiol. Immunol. Infect. 37 (2004) 350-358
20. Laing F.P., Ramotar K., Read R.R., Alfieri N., Kureishi A., Henderson E.A., and Louie T.J. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J. Clin. Microbiol. 33 (1995) 513-518
21. Liaw S.J., Teng L.J., Hsueh P.R., Ho S.W., and Luh K.T. In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia. J Formos Med Assoc 101 (2002) 495-501
22. Lin W.P., Lai H.L., Liu Y.L., Chiung Y.M., Shiau C.Y., Han J.M., Yang C.M., and Liu Y.T. Effect of melanin produced by a recombinant Escherichia coli on antibacterial activity of antibiotics. J. Microbiol. Immunol. Infect. 38 (2005) 320-326
23. Marchac V., Equi A., Le Bihan-Benjamin C., Hodson M., and Bush A. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur. Respir. J. 23 (2004) 98-102
24. Muder R.R., Harris A.P., Muller S., Edmond M., Chow J.W., Papadakis K., Wagener M.W., Bodey G.P., and Steckelberg J.M. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin. Infect. Dis. 22 (1996) 508-512
25. Nicholson A.M., Castle D., Akpaka P., Tennant I., and Nelson M. The emergence of Stenotrophomonas maltophilia as a significant nosocomial pathogen at the University Hospital of the West Indies. West Indian Med. J. 53 (2004) 17-22
26. Nicodemo A.C., Araujo M.R., Ruiz A.S., and Gales A.C. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J. Antimicrob. Chemother. 53 (2004) 604-608
27. Nosanchuk J.D., and Casadevall A. The contribution of melanin to microbial pathogenesis. Cell Microbiol. 5 (2003) 203-223
28. Ploy M.C., Denis F., Courvalin P., and Lambert T. Molecular characterization of integrons in Acinetobacter baumannii: description of a hybrid class 2 integron. Antimicrob. Agents Chemother. 44 (2000) 2684-2688
29. Rowe-Magnus D., and Mazel D.A. Resistance gene capture. Curr. Opin. Microbiol. 2 (1999) 483-488
30. San Gabriel P., Zhou J., Tabibi S., Chen Y., Trauzzi M., and Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48 (2004) 168-171
31. Senol E. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen. J. Hosp. Infect. 57 (2004) 1-7
32. Spencer R.C. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J. Hosp. Infect. 30 Suppl (1995) 453-464
33. Villarino M.E., Stevens L.E., Schable B., Mayers G., Miller J.M., Burke J.P., and Jarvis W.R. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect. Control Hosp. Epidemiol. 13 (1992) 201-206
34. Wang W.S., Liu C.P., Lee C.M., and Huang F.Y. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J. Microbiol. Immunol. Infect. 37 (2004) 359-365
35. Zelenitsky S.A., Iacovides H., Ariano R.E., and Harding G.K. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 51 (2005) 39-43
36. Zgurskaya H.I., and Nikaido H. Multidrug resistance mechanisms: drug efflux across two membranes. Mol. Microbiol. 37 (2000) 219-225